KR102360233B1 - Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof - Google Patents
Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof Download PDFInfo
- Publication number
- KR102360233B1 KR102360233B1 KR1020210039918A KR20210039918A KR102360233B1 KR 102360233 B1 KR102360233 B1 KR 102360233B1 KR 1020210039918 A KR1020210039918 A KR 1020210039918A KR 20210039918 A KR20210039918 A KR 20210039918A KR 102360233 B1 KR102360233 B1 KR 102360233B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- composition
- preventing
- present
- bcc
- Prior art date
Links
- 241000186840 Lactobacillus fermentum Species 0.000 title claims abstract description 43
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims abstract description 43
- 230000000694 effects Effects 0.000 title claims description 27
- 208000025157 Oral disease Diseases 0.000 title abstract description 7
- 208000030194 mouth disease Diseases 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims description 81
- 230000000844 anti-bacterial effect Effects 0.000 claims description 42
- 208000002925 dental caries Diseases 0.000 claims description 32
- 208000028169 periodontal disease Diseases 0.000 claims description 32
- 206010006326 Breath odour Diseases 0.000 claims description 31
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 22
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 21
- 239000006166 lysate Substances 0.000 claims description 21
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 108010082340 Arginine deiminase Proteins 0.000 claims description 15
- 102000003814 Interleukin-10 Human genes 0.000 claims description 15
- 108090000174 Interleukin-10 Proteins 0.000 claims description 15
- 241000194019 Streptococcus mutans Species 0.000 claims description 15
- 230000006872 improvement Effects 0.000 claims description 14
- 244000005700 microbiome Species 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 9
- 229910052725 zinc Inorganic materials 0.000 claims description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 210000000214 mouth Anatomy 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 description 23
- 239000000047 product Substances 0.000 description 20
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 241000589892 Treponema denticola Species 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 6
- 241000193987 Streptococcus sobrinus Species 0.000 description 6
- 241000975185 Weissella cibaria Species 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 5
- 241001135221 Prevotella intermedia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000003239 periodontal effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- 240000001929 Lactobacillus brevis Species 0.000 description 4
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 4
- 241000194008 Streptococcus anginosus Species 0.000 description 4
- 241000194043 Streptococcus criceti Species 0.000 description 4
- 241000194026 Streptococcus gordonii Species 0.000 description 4
- 241000194052 Streptococcus ratti Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- -1 leukotrien Chemical compound 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003464 sulfur compounds Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000194023 Streptococcus sanguinis Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241001135235 Tannerella forsythia Species 0.000 description 2
- 241000120020 Tela Species 0.000 description 2
- 208000008312 Tooth Loss Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 206010034535 Periodontal destruction Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000036344 tooth staining Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 구강염증, 치아우식증 및 구취를 포함하는 구강질환의 예방, 개선 또는 치료 효과를 가지는 락토바실러스 퍼멘텀 균주 및 이의 용도에 관한 것이다.The present invention relates to a Lactobacillus fermentum strain having an effect of preventing, improving or treating oral diseases, including oral inflammation, dental caries and bad breath, and uses thereof.
치주질환은 세균에 의해 야기되는 치아지지 조직의 염증상태로서, 출혈, 치주낭의 형성 및 치조골의 파괴 등으로 인하여 치아의 상실을 가져오는 질환이다. 세균의 집락형성, 세균의 치주조직 침투 및 치주조직이 파괴되는 과정으로 진행된다. 특히 red complex 에 속하는 포르피로모나스 진지발리스(Porphyromonas gingivalis) 및 트레포네마 덴티콜라(Treponema denticola)와, orange complex 에 속하는 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum) 이 치주질환의 가장 중요한 원인균주이다.Periodontal disease is an inflammatory condition of the tooth supporting tissue caused by bacteria, and is a disease that causes tooth loss due to bleeding, formation of periodontal pockets, and destruction of alveolar bone. It proceeds in the process of colonization of bacteria, invasion of periodontal tissue by bacteria, and destruction of periodontal tissue. In particular, Porphyromonas gingivalis belonging to the red complex and Treponema denticola , and Fusobacterium nucleatum belonging to the orange complex are the most important causative strains of periodontal disease. .
치주조직 파괴와 염증은 그람 음성 혐기성 세균의 대사 산물인 황화수소, 암모니아 및 유독한 아민과 같은 세포 독소와 그람 음성 혐기성 세균의 세포벽 구성분인 리포폴리사카라이드(Lipopolysaccharide)와 같은 내독소에 의해 직접 조직이 파괴되거나 또는 생체 면역계를 자극하여 자극된 체액성 및 세포성 면역계의 작용으로인해 세포 외부로 분비된 활성산소, 프로스타글란딘(prostaglandin), 루코트리엔(leukotrien), 히스타민(histamine), 인터루킨(interleukin)등의 다양한 사이토카인에 의해 염증이 유발된다.Periodontal tissue destruction and inflammation are directly caused by cytotoxins such as hydrogen sulfide, ammonia, and toxic amines, which are metabolites of Gram-negative anaerobes, and endotoxins such as lipopolysaccharide, a cell wall component of Gram-negative anaerobes. Active oxygen, prostaglandin, leukotrien, histamine, interleukin, secreted to the outside of cells due to the action of the humoral and cellular immune system that is destroyed or stimulated by stimulating the biological immune system ) is induced by various cytokines such as
염증 반응이 시작되면 염증성 사이토카인인 IL-12는 Th0 세포로부터 Th1 세포로 분화시키고, 대식세포를 활성화시켜 염증반응을 증진시킨다. 이러한 염증은 골을 생성하는 기능은 저하시키고, 골을 흡수하는 기능은 증가시켜 치조골이 점점 소실되고 파괴되어 결국 치아를 상실하게 된다. 반면에 IL-10과 같은 항염증성 사이토카인 생성이 증가되면 조절 T세포(Tregs)를 증가시켜 활성화된 대식세포를 제어해 염증반응을 저하시키고, 건강한 치주 상태를 유지하게 된다.When the inflammatory response starts, IL-12, an inflammatory cytokine, differentiates from Th0 cells into Th1 cells, and activates macrophages to enhance the inflammatory response. This inflammation lowers the function of generating bone and increases the function of resorbing the bone, resulting in the loss and destruction of alveolar bone, eventually leading to tooth loss. On the other hand, when the production of anti-inflammatory cytokines such as IL-10 is increased, regulatory T cells (Tregs) are increased to control activated macrophages, thereby lowering the inflammatory response and maintaining a healthy periodontal state.
아르기닌 데이미나아제(Arginine deiminase)는 아르기닌을 시트룰린과 암모니아로 분해시키는 효소이다.Arginine deiminase is an enzyme that breaks down arginine into citrulline and ammonia.
Inducible nitric oxide synthase(iNOS)는 외부 상처에 대한 반응 및 염증 같은 면역방어기전의 다양한 과정을 매개하는 cytokine인 interleukin-1(IL-1)이나 tumor necrosis factor(TNF), lipopolysaccharide(LPS)등에 의해 유도되며 아르기닌으로부터 nitric oxide(NO) 합성에 관여한다. iNOS에 의해 생성된 NO는 prostaglandin E2(PGE2), TNFα, IL-6와 같은 cytokine의 생성을 증가시켜 치주조직에서 염증세포와 면역세포를 활성화시켜 치조골 파괴를 일으킬 수 있다. Inducible nitric oxide synthase (iNOS) is induced by interleukin-1 (IL-1), tumor necrosis factor (TNF), lipopolysaccharide (LPS), cytokines that mediate various processes of immune defense mechanisms such as response to external wounds and inflammation. It is involved in the synthesis of nitric oxide (NO) from arginine. NO generated by iNOS increases the production of cytokines such as prostaglandin E 2 (PGE 2 ), TNFα, and IL-6, thereby activating inflammatory cells and immune cells in periodontal tissue, thereby causing alveolar bone destruction.
따라서 아르기닌 데이미나아제활성이 있는 균주는 NO의 전구체인 아르기닌을 감소시켜 치주염을 예방 또는 개선시킬 수 있다.Therefore, strains with arginine deiminase activity can prevent or improve periodontitis by reducing arginine, a precursor of NO.
치아우식증은 입 안에서 서식하는 박테리아에 의해 설탕, 전분 등이 분해되면서 생성된 산에 의해 치아의 법랑질이 손상되어 발생하는 증상을 말한다. 이는 치아의 손상뿐만 아니라 심한 통증, 잇몸 부종, 구취 등을 유발하고 다른 구강질환으로 진행될 수 있으며, 우식으로 인해 벌어진 잇몸 틈사이로 세균이 침입해 2차 감염이 일어날 수도 있다. 치아우식증의 대표적인 원인균으로는 스트렙토코커스 뮤탄스(Streptococcus mutans)와 스트렙토코커스 소브리누스(Streptococcus sobrinus)가 있으며 치아우식증을 예방하기 위해 상기 언급한 유발균의 생장을 억제, 사멸하는 제품들이 개발되고 있다.Dental caries is a condition that occurs when the enamel of the teeth is damaged by acids produced when sugar and starch are decomposed by bacteria living in the mouth. This causes not only damage to the teeth, but also severe pain, swelling of the gums, bad breath, and can progress to other oral diseases. Typical causative bacteria of dental caries include Streptococcus mutans and Streptococcus sobrinus , and products that inhibit the growth of the above-mentioned causative bacteria and kill them are being developed to prevent dental caries. .
구취는 구강 또는 비강을 통하여 나오는 불쾌한 냄새로 정의되며, 구취의 원인으로는 구강 세균에 의한 음식물 부패와 그 대사산물인 휘발성 황 화합물 때문인 것으로 알려져 있다. 휘발성 황 화합물은 황을 함유하는 시스테인과 메티오닌과 같은 아미노산, 펩타이드 및 단백질 기질 존재 시 혐기성 세균에 의해 생성된다. 시스테인에서 황화수소가 만들어지고 메티오닌에 의해서 메틸머캅탄, 디메틸설파이드가 생성되며 이중 황화수소와 메틸머캅탄이 구취의 주된 원인인자로 90%를 차지한다. 그람 음성 혐기성 세균이 휘발성 황 화합물 생성 능력을 가지며 특히 치주질환 원인 균주로 알려진 포르피로모나스 진지발리스(Porphyromonas gingivalis), 트레포네마 덴티콜라(Treponema denticola), 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum), 프레보텔라 인터미디아(Prevotella intermedia), 박테로이데스 폴시튜스(Bacteroides forsythus)가 많은 양의 황화수소와 메틸머캅탄을 생성한다고 보고되고 있다.Halitosis is defined as an unpleasant odor emanating from the oral cavity or nasal passages, and it is known that the cause of bad breath is food spoilage by oral bacteria and volatile sulfur compounds that are metabolites thereof. Volatile sulfur compounds are produced by anaerobic bacteria in the presence of sulfur-containing amino acids such as cysteine and methionine, peptides and protein substrates. Hydrogen sulfide is produced from cysteine, and methyl mercaptan and dimethyl sulfide are produced by methionine. Of these, hydrogen sulfide and methyl mercaptan are the main causes of bad breath and account for 90% of them. Gram-negative anaerobic bacteria have the ability to produce volatile sulfur compounds, and in particular Porphyromonas gingivalis , which is known as a strain causing periodontal disease, Treponema denticola , Fusobacterium nucleatum , Prevotella intermedia ( Prevotella intermedia ), Bacteroides forsythus ) It has been reported that a large amount of hydrogen sulfide and methyl mercaptan are produced.
구강 세균을 제어하기 위해 항생제, 항균제, 항염제가 사용되고 있다. 그러나, 항생제는 분리된 치주질환 균주에서 내성을 나타낸 사례가 보고되어 심각한 문제가 되고 있다. 항균제는 치아 염색 또는 구강점막의 작열감 등의 부작용을 초래한다. 또한, 불소 화합물이 함유된 구강청결제, 치약 및 가글액 등은 일부 성분에 대한 안전성 이슈와 논란이 보고되고 있다. 구강 내 사각지대에 있는 치주질환 원인균은 억제가 어렵고 유해균의 지속적인 성장으로 인해 이러한 치료제는 일시적인 제어일 뿐이라는 문제가 있다.Antibiotics, antibacterial agents, and anti-inflammatory drugs are being used to control oral bacteria. However, antibiotics have become a serious problem because cases showing resistance to isolated periodontal disease strains have been reported. Antibacterial agents cause side effects such as tooth staining or burning of the oral mucosa. In addition, safety issues and controversies have been reported for some ingredients such as mouthwashes, toothpastes, and gargles containing fluorine compounds. Periodontal disease causative bacteria in the oral cavity are difficult to suppress, and due to the continuous growth of harmful bacteria, there is a problem that these treatments are only temporary control.
따라서 구강염증, 치아우식증 및 구취제거와 같은 구강 질환에 안전하고 효과적인 균주에 대한 연구가 필요한 실정이다.Therefore, there is a need for research on safe and effective strains for oral diseases such as oral inflammation, dental caries, and removal of bad breath.
상기와 같은 배경하에서, 본 발명자들은 하기와 같은 신규 미생물 및 이의 용도를 제공하고자 한다. Under the above background, the present inventors intend to provide the following novel microorganisms and uses thereof.
본 발명의 일측면은 락토바실러스 속의 균주로 항균 활성이 우수한 신규한 균주 및 이의 제제를 제공하고자 한다.One aspect of the present invention is to provide a novel strain excellent in antibacterial activity as a strain of the genus Lactobacillus and a preparation thereof.
본 발명의 목적은 수탁번호 KCTC 14461BP로 기탁된 락토바실러스 퍼멘텀 BCC-LF-01 (Lactobacillus fermentum BCC-LF-01) 균주를 제공하기 위한 것이다.It is an object of the present invention to provide a Lactobacillus fermentum BCC-LF-01 ( Lactobacillus fermentum BCC-LF-01) strain deposited with accession number KCTC 14461BP.
본 발명의 다른 목적은 상기 락토바실러스 퍼멘텀 BCC-LF-01 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 치주질환 예방, 개선 또는 치료 방법을 제공하고자 한다.Another object of the present invention is the Lactobacillus Fermentum BCC-LF-01 strain; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It is intended to provide a method of preventing, improving or treating periodontal disease, including the step of using one or more of them.
본 발명의 또 다른 목적은 상기 락토바실러스 퍼멘텀 BCC-LF-01 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 치아우식증의 예방, 개선 또는 치료 방법을 제공하고자 한다.Another object of the present invention is the Lactobacillus Fermentum BCC-LF-01 strain; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It is intended to provide a method for preventing, improving or treating dental caries, including the step of using one or more of them.
본 발명의 또 다른 목적은 상기 락토바실러스 퍼멘텀 BCC-LF-01 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 구취제거 또는 예방 방법을 제공하고자 한다.Another object of the present invention is the Lactobacillus Fermentum BCC-LF-01 strain; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It is intended to provide a method for removing or preventing bad breath, including the step of using one or more of them.
본 발명의 또 하나의 다른 목적은 상기 락토바실러스 퍼멘텀 BCC-LF-01 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 치주질환, 치아우식증 또는 구취 예방, 개선 또는 치료용 조성물을 제공하고자 한다.Another object of the present invention is the Lactobacillus Fermentum BCC-LF-01 strain; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; To provide a composition for preventing, improving or treating periodontal disease, dental caries, or bad breath, including the step of using one or more of them.
본 발명의 목적은 이상에서 언급한 목적으로 제한되지 않는다. 본 발명의 목적은 이하의 설명으로 보다 분명해 질 것이며, 특허청구범위에 기재된 수단 및 그 조합으로 실현될 것이다.The object of the present invention is not limited to the object mentioned above. The object of the present invention will become clearer from the following description, and will be realized by means and combinations thereof described in the claims.
상기 목적을 달성하기 위하여, 하기의 해결 수단을 제공한다.In order to achieve the above object, the following solutions are provided.
본 발명의 일측면은 구강 유해 미생물에 항균력을 갖는 락토바실러스 퍼멘텀 (Lactobacillus fermentum) 균주를 제공한다.One aspect of the present invention provides a Lactobacillus fermentum ( Lactobacillus fermentum ) strain having antibacterial activity against harmful oral microorganisms.
본 발명의 일측면에 있어서, 상기 균주는 IL-12의 생성을 감소시키며, IL-10의 생성을 증가시키는 항염 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain that reduces the production of IL-12 and has an anti-inflammatory effect that increases the production of IL-10.
본 발명의 일측면에 있어서, 상기 균주는 아르기닌 데이미나아제(Arginine deiminase) 활성을 갖는 항염 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain having an anti-inflammatory effect having an arginine deiminase activity.
본 발명의 일측면에 있어서, 상기 균주는 치주질환 예방, 개선 또는 치료 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain that has a periodontal disease prevention, improvement or treatment effect.
본 발명의 일측면에 있어서, 상기 균주는 치주질환 유발 미생물인 포르피로모나스 진지발리스(Porphyromonas gingivalis), 트레포네마 덴티콜라(Treponema denticola), 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum), 프레보텔라 인터미디아(Prevotella intermedia) 및 아그레가티박터 액티노마이세템코미탄스(Aggregatibacter actinomycetemcomitans) 에 항균력이 있는 균주를 제공한다.In one aspect of the present invention, the strain is a periodontal disease-causing microorganism Porphyromonas gingivalis ( Porphyromonas gingivalis ), Treponema denticola ( Treponema denticola ), Fusobacterium nucleatum ( Fusobacterium nucleatum ), Prevo Tela intermedia ( Prevotella intermedia ) and Aggregatibacter actinomycetemcomitans ( Aggregatibacter actinomycetemcomitans ) It provides a strain with antibacterial activity.
본 발명의 일측면에 있어서, 상기 균주는 치아우식증 예방, 개선 또는 치료 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain having a dental caries prevention, improvement or treatment effect.
본 발명의 일측면에 있어서, 상기 균주는 치아우식증 유발 미생물인 스트렙토코커스 뮤탄스(Streptococcus mutans), 스트렙토코커스 상귀니스(Streptococcus sanguinis), 스트렙토코커스 소브리누스(Streptococcus sobrinus), 스트렙토코커스 라티(Streptococcus ratti), 스트렙토코커스 크리세티(Streptococcus criceti), 스트렙토코커스 안지노수스(Streptococcus anginosus) 및 스트렙토코커스 고도니(Streptococcus gordonii) 에 항균력이 있는, 균주를 제공한다.In one aspect of the present invention, the strain is a dental caries-inducing microorganism Streptococcus mutans ( Streptococcus mutans ), Streptococcus sanguinis ), Streptococcus sobrinus ( Streptococcus sobrinus ), Streptococcus ratti ( Streptococcus ratti ) ), Streptococcus criceti ( Streptococcus criceti ), Streptococcus anginosus ( Streptococcus anginosus ) and Streptococcus gordonii ( Streptococcus gordonii ) With antibacterial activity, it provides a strain.
본 발명의 일측면에 있어서, 상기 균주는 구취제거 또는 예방 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain having an effect of removing or preventing bad breath.
본 발명의 일측면에 있어서, 상기 구취 발생 미생물은 포르피로모나스 진지발리스(Porphyromonas gingivalis), 트레포네마 덴티콜라(Treponema denticola) 및 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum)에 항균력이 있는 균주를 제공한다.In one aspect of the present invention, the bad breath-generating microorganism is Porphyromonas gingivalis ( Porphyromonas gingivalis ), Treponema denticola ( Treponema denticola ) and Fusobacterium nucleatum ( Fusobacterium nucleatum ) A strain with antibacterial activity to provide.
본 발명의 일측면에 있어서, 상기 균주는 서열번호 1의 염기서열을 포함하는 16S rRNA를 갖는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain having 16S rRNA comprising the nucleotide sequence of SEQ ID NO: 1.
본 발명의 일측면에 있어서, 상기 균주는 동일속 동일종의 락토바실러스 퍼멘텀 KCTC 5049와는 다른 염기서열을 갖는 락토바실러스 퍼멘텀 BCC-LF-01인, 균주를 제공한다.In one aspect of the present invention, the strain provides a Lactobacillus Fermentum BCC-LF-01 having a different nucleotide sequence from the Lactobacillus Fermentum KCTC 5049 of the same genus and the same species, the strain.
본 발명의 일측면에 있어서, 상기 균주는 기탁번호가 KCTC 14461BP인, 균주를 제공한다.In one aspect of the present invention, the strain provides an accession number of KCTC 14461BP, the strain.
본 발명의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 포함하는 미생물 제제를 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a microbial preparation comprising one or more of.
본 발명의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 치주 질환의 예방, 개선 또는 치료가 필요한 대상에게 치주 질환을 예방, 개선 또는 치료하는 방법을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a method for preventing, improving or treating periodontal disease to a subject in need of prevention, improvement or treatment of periodontal disease, including the step of using one or more of them.
본 발명의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 치아우식증의 예방, 개선 또는 치료가 필요한 대상에게 치아우식증을 예방, 개선 또는 치료하는 방법을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a method for preventing, improving or treating dental caries to a subject in need of prevention, improvement or treatment of dental caries, including the step of using one or more of them.
본 발명의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 구취 예방 또는 제거가 필요한 대상에게 구취를 예방 또는 제거하는 방법을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a method for preventing or removing bad breath to a subject in need of preventing or removing bad breath, including the step of using one or more of them.
본 발명의 또 하나의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 포함하는 치주 질환의 예방, 개선 또는 치료용 조성물을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a composition for the prevention, improvement or treatment of periodontal disease comprising one or more of.
일 구현예에서, 상기 조성물은 아연을 더 포함하는, 치주 질환의 예방, 개선 또는 치료용 조성물을 제공한다.In one embodiment, the composition provides a composition for preventing, improving or treating periodontal disease, further comprising zinc.
일 구현예에서, 상기 조성물은 건강기능식품 또는 의약품 조성물인, 치주 질환의 예방, 개선 또는 치료용 조성물을 제공한다.In one embodiment, the composition provides a composition for preventing, improving or treating periodontal disease, which is a health functional food or pharmaceutical composition.
본 발명의 또 하나의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 포함하는 치아우식증의 예방, 개선 또는 치료용 조성물을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a composition for preventing, improving or treating dental caries comprising at least one of them.
일 구현예에서, 상기 조성물은 아연을 더 포함하는, 치아우식증의 예방, 개선 또는 치료용 조성물을 제공한다.In one embodiment, the composition provides a composition for preventing, improving or treating dental caries, further comprising zinc.
일 구현예에서, 상기 조성물은 건강기능식품 또는 의약품 조성물인, 치아우식증의 예방, 개선 또는 치료용 조성물을 제공한다.In one embodiment, the composition provides a composition for preventing, improving or treating dental caries, which is a health functional food or pharmaceutical composition.
본 발명의 또 하나의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 포함하는 구취 제거 또는 예방용 조성물을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a composition for removing or preventing bad breath comprising at least one of.
일 구현예에서, 상기 조성물은 아연을 더 포함하는, 구취 제거 또는 예방용 조성물을 제공한다.In one embodiment, the composition provides a composition for removing or preventing bad breath, further comprising zinc.
일 구현예에서, 상기 조성물은 건강기능식품 또는 의약품 조성물인, 구취 제거 또는 예방용 조성물을 제공한다.In one embodiment, the composition provides a health functional food or pharmaceutical composition, a composition for removing or preventing bad breath.
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 항염 효과가 우수하다. The strain according to one aspect of the present invention and a composition comprising the same have excellent anti-inflammatory effects.
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 IL-12의 생성을 감소시키며, IL-10의 생성을 증가시키는 항염 효과가 우수하다The strain according to an aspect of the present invention and a composition comprising the same reduce the production of IL-12, and have excellent anti-inflammatory effects that increase the production of IL-10
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 아르기닌 데이미나아제를 생성하는 항염 효과가 우수하다The strain according to one aspect of the present invention and a composition comprising the same have excellent anti-inflammatory effect to produce arginine deiminase
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 치주 질환 원인균에 대한 항균 효과가 우수하다.The strain according to an aspect of the present invention and a composition comprising the same have excellent antibacterial effects against periodontal disease causative bacteria.
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 치아우식증 원인균에 대한 항균 효과가 우수하다.The strain and the composition comprising the same according to one aspect of the present invention have excellent antibacterial effects against the bacteria causing dental caries.
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 구취 발생 미생물에 대항 항균 효과가 우수하다.The strain according to an aspect of the present invention and a composition comprising the same have excellent antibacterial effects against bad breath-generating microorganisms.
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 잇몸 질환 개선 효과가 우수하다.The strain according to one aspect of the present invention and a composition comprising the same are excellent in improving the effect of gum disease.
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 치주질환, 치아 우식증 또는 구취제거 개선 효과가 우수하다.The strain according to an aspect of the present invention and a composition comprising the same are excellent in improving effect of periodontal disease, dental caries or bad breath removal.
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 포르피로모나스 진지발리스(Porphyromonas gingivalis)에 대한 항균 효과가 우수하다. The strain according to one aspect of the present invention and a composition comprising the same have excellent antibacterial effects against Porphyromonas gingivalis .
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 트레포네마 덴티콜라(Treponema denticola)에 대한 항균 효과가 우수하다.The strain according to an aspect of the present invention and a composition comprising the same have excellent antibacterial effects against Treponema denticola .
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum)에 대한 항균 효과가 우수하다. The strain according to one aspect of the present invention and a composition comprising the same are excellent in antibacterial effect against Fusobacterium nucleatum .
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 프레보텔라 인터미디아(Prevotella intermedia)에 대한 항균 효과가 우수하다. The strain according to an aspect of the present invention and a composition comprising the same have excellent antibacterial effects against Prevotella intermedia .
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 박테로이데스 폴시튜스(Bacteroides forsythus)에 대한 항균 효과가 우수하다. The strain according to an aspect of the present invention and a composition comprising the same are excellent in antibacterial effect against Bacteroides forsythus .
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 아그레가티박터 액티노마이세템코미탄스(Aggregatibacter actinomycetemcomitans)에 대한 항균 효과가 우수하다.The strain according to one aspect of the present invention and a composition comprising the same are excellent in antibacterial effect against Aggregatibacter actinomycetemcomitans .
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 스트렙토코커스 뮤탄스(Streptococcus mutans)에 대한 항균 효과가 우수하다. The strain according to one aspect of the present invention and a composition comprising the same are excellent in antibacterial effect against Streptococcus mutans .
본 발명의 일측면에 따른 균주 및 이를 포함하는 조성물은 스트렙토코커스 소브리누스(Streptococcus sobrinus)에 대한 항균 효과가 우수하다. The strain and the composition comprising the same according to one aspect of the present invention have excellent antibacterial effects against Streptococcus sobrinus .
본 발명의 효과는 이상에서 언급한 효과로 한정되지 않는다. 본 발명의 효과는 이하의 설명에서 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 할 것이다.The effects of the present invention are not limited to the above-mentioned effects. It should be understood that the effects of the present invention include all effects that can be inferred from the following description.
도 1은 신규 Lactobacillus fermentum BCC-LF-01 균주(KCTC 14461BP)의 당 이용성 확인 결과이다.
도 2은 신규 Lactobacillus fermentum BCC-LF-01 균주(KCTC 14461BP)의 계통도를 나타낸 것이다.
도 3는 신규 Lactobacillus fermentum BCC-LF-01과 Lactobacillus fermentum KCTC 5049의 서열 간 차이를 나타낸 것이다.
도 4a는 분리된 32균주 중 항염 효과를 가지는 11균주를 도식화한 그래프이고 도 4b는 균주의 IL-12 생성량을, 도 4c는 균주의 IL-10 생성량을 나타낸 그래프이다.
도 5a는 분리된 균주의 스트렙토코커스 뮤탄스(Streptococcus mutans)에 대한 항균효과를, 5b는 포르피로모나스 진지발리스(Porphyromonas gingivalis)에 대한 항균효과를, 5c는 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum)에 대한 항균효과를 나타낸 그래프이다.1 is a result of confirming sugar availability of a novel Lactobacillus fermentum BCC-LF-01 strain (KCTC 14461BP).
Figure 2 shows a phylogenetic diagram of a novel Lactobacillus fermentum BCC-LF-01 strain (KCTC 14461BP).
Figure 3 shows the difference between the sequences of the novel Lactobacillus fermentum BCC-LF-01 and Lactobacillus fermentum KCTC 5049.
Figure 4a is a graph schematically showing 11 strains having an anti-inflammatory effect among the 32 isolated strains, Figure 4b is a graph showing the IL-12 production amount of the strain, Figure 4c is a graph showing the IL-10 production amount of the strain.
Figure 5a is the isolated strain Streptococcus mutans ( Streptococcus mutans ) Antibacterial effect, 5b is Porphyromonas gingivalis ( Porphyromonas gingivalis ) Antibacterial effect on, 5c is Fusobacterium nucleatum ( Fusobacterium nucleatum ) ) is a graph showing the antibacterial effect against
이상의 본 발명의 목적들, 다른 목적들, 특징들 및 이점들은 첨부된 도면과 관련된 이하의 바람직한 실시예들을 통해서 쉽게 이해될 것이다. 그러나 본 발명은 여기서 설명되는 실시예들에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 실시예들은 개시된 내용이 철저하고 완전해질 수 있도록 그리고 통상의 기술자에게 본 발명의 사상이 충분히 전달될 수 있도록 하기 위해 제공되는 것이다.The above objects, other objects, features and advantages of the present invention will be easily understood through the following preferred embodiments in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, the embodiments introduced herein are provided so that the disclosed subject matter may be thorough and complete, and that the spirit of the present invention may be sufficiently conveyed to those skilled in the art.
본 명세서에서, "포함하다" 또는 "가지다" 등의 용어는 명세서 상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부분품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.In the present specification, terms such as "comprise" or "have" are intended to designate that a feature, number, step, operation, component, part, or combination thereof described in the specification exists, but one or more other features It is to be understood that it does not preclude the possibility of the presence or addition of numbers, steps, operations, components, parts, or combinations thereof.
본 명세서에 있어서, 범위가 변수에 대해 기재되는 경우, 상기 변수는 상기 범위의 기재된 종료점들을 포함하는 기재된 범위 내의 모든 값들을 포함하는 것으로 이해될 것이다. 예를 들면, "5 내지 10"의 범위는 5, 6, 7, 8, 9, 및 10의 값들뿐만 아니라 6 내지 10, 7 내지 10, 6 내지 9, 7 내지 9 등의 임의의 하위 범위를 포함하고, 5.5, 6.5, 7.5, 5.5 내지 8.5 및 6.5 내지 9 등과 같은 기재된 범위의 범주에 타당한 정수들 사이의 임의의 값도 포함하는 것으로 이해될 것이다. 또한 예를 들면, "10% 내지 30%"의 범위는 10%, 11%, 12%, 13% 등의 값들과 30%까지를 포함하는 모든 정수들뿐만 아니라 10% 내지 15%, 12% 내지 18%, 20% 내지 30% 등의 임의의 하위 범위를 포함하고, 10.5%, 15.5%, 25.5% 등과 같이 기재된 범위의 범주 내의 타당한 정수들 사이의 임의의 값도 포함하는 것으로 이해될 것이다. In this specification, when a range is described for a variable, the variable will be understood to include all values within the stated range including the stated endpoints of the range. For example, a range of “5 to 10” includes the values of 5, 6, 7, 8, 9, and 10, as well as any subranges such as 6 to 10, 7 to 10, 6 to 9, 7 to 9, etc. It will be understood to include any value between integers that are appropriate for the scope of the recited range, such as 5.5, 6.5, 7.5, 5.5 to 8.5 and 6.5 to 9, and the like. Also for example, ranges from "10% to 30%" include values of 10%, 11%, 12%, 13%, etc. and all integers up to and including 30%, as well as 10% to 15%, 12% to It will be understood to include any subranges such as 18%, 20% to 30%, etc., as well as any value between reasonable integers within the scope of the recited ranges, such as 10.5%, 15.5%, 25.5%, and the like.
이하, 본 발명을 구체적으로 설명한다. Hereinafter, the present invention will be specifically described.
본 발명에 따른 락토바실러스 퍼멘텀 BCC-LF-01(Lactobacillus fermentum BCC-LF-01)균주는 항염 효과를 가지면서, 치주질환 및 치아우식증 유발균에 대한 항균활성을 가지는 바, 치주질환, 치아우식증 또는 구취 예방, 개선, 또는 치료 효과를 제공한다Lactobacillus fermentum BCC-LF-01 ( Lactobacillus fermentum BCC-LF-01) strain according to the present invention has an anti-inflammatory effect, and has antibacterial activity against periodontal disease and dental caries-inducing bacteria, periodontal disease, dental caries or provides an effect of preventing, ameliorating, or treating halitosis.
이하, 본 발명의 다양한 측면에 대하여 설명한다.Hereinafter, various aspects of the present invention will be described.
본 발명의 일측면에 있어서, 상기 균주는 IL-12의 생성을 감소시키며, IL-10의 생성을 증가시키는 항염 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain that reduces the production of IL-12 and has an anti-inflammatory effect that increases the production of IL-10.
본 발명의 일측면에 있어서, 상기 균주는 아르기닌 데이미나아제를 생성하는 항염 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain has an anti-inflammatory effect to produce arginine deiminase, it provides a strain.
본 발명의 일측면은 구강 유해 미생물에 항균력을 갖는 락토바실러스 퍼멘텀 (Lactobacillus fermentum ) 균주를 제공한다.One aspect of the present invention provides a Lactobacillus fermentum ( Lactobacillus fermentum ) strain having antibacterial activity against harmful oral microorganisms.
본 발명의 일측면에 있어서, 상기 균주는 치주질환 예방, 개선 또는 치료 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain that has a periodontal disease prevention, improvement or treatment effect.
본 발명의 일측면에 있어서, 상기 균주는 치주질환 유발 미생물인 포르피로모나스 진지발리스(Porphyromonas gingivalis), 트레포네마 덴티콜라(Treponema denticola), 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum), 프레보텔라 인터미디아(Prevotella intermedia) 및 아그레가티박터 액티노마이세템코미탄스(Aggregatibacter actinomycetemcomitans)에 항균력이 있는 균주를 제공한다.In one aspect of the present invention, the strain is a periodontal disease-causing microorganism Porphyromonas gingivalis ( Porphyromonas gingivalis ), Treponema denticola ( Treponema denticola ), Fusobacterium nucleatum ( Fusobacterium nucleatum ), Prevo Tela intermedia ( Prevotella intermedia ) and Aggregatibacter actinomycetemcomitans ( Aggregatibacter actinomycetemcomitans ) It provides a strain with antibacterial activity.
본 발명의 일측면에 있어서, 상기 균주는 치아우식증 예방, 개선 또는 치료 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain having a dental caries prevention, improvement or treatment effect.
본 발명의 일측면에 있어서, 상기 균주는 치아우식증 유발 미생물인 스트렙토코커스 뮤탄스(Streptococcus mutans), 스트렙토코커스 상귀니스(Streptococcus sanguinis), 스트렙토코커스 소브리누스(Streptococcus sobrinus), 스트렙토코커스 라티(Streptococcus ratti), 스트렙토코커스 크리세티(Streptococcus criceti), 스트렙토코커스 안지노수스(Streptococcus anginosus) 및 스트렙토코커스 고도니(Streptococcus gordonii) 에 항균력이 있는, 균주를 제공한다.In one aspect of the present invention, the strain is a dental caries-inducing microorganism Streptococcus mutans ( Streptococcus mutans ), Streptococcus sanguinis ), Streptococcus sobrinus ( Streptococcus sobrinus ), Streptococcus ratti ( Streptococcus ratti ) ), Streptococcus criceti ( Streptococcus criceti ), Streptococcus anginosus ( Streptococcus anginosus ) and Streptococcus gordonii ( Streptococcus gordonii ) With antibacterial activity, it provides a strain.
본 발명의 일측면에 있어서, 상기 균주는 구취제거 또는 예방 효과가 있는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain having an effect of removing or preventing bad breath.
본 발명의 일측면에 있어서, 상기 구취 발생 미생물은 포르피로모나스 진지발리스(Porphyromonas gingivalis), 트레포네마 덴티콜라(Treponema denticola) 및 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum)에 항균력이 있는 균주를 제공한다.In one aspect of the present invention, the bad breath-generating microorganism is Porphyromonas gingivalis ( Porphyromonas gingivalis ), Treponema denticola ( Treponema denticola ) and Fusobacterium nucleatum ( Fusobacterium nucleatum ) A strain with antibacterial activity to provide.
본 발명의 일측면에 있어서, 상기 균주는 서열번호 1의 염기서열을 포함하는 16S rRNA를 갖는, 균주를 제공한다.In one aspect of the present invention, the strain provides a strain having 16S rRNA comprising the nucleotide sequence of SEQ ID NO: 1.
본 발명의 일측면에 있어서, 상기 균주는 락토바실러스 퍼멘텀 BCC-LF-01인, 균주를 제공한다.In one aspect of the present invention, the strain is Lactobacillus Fermentum BCC-LF-01, it provides a strain.
본 발명의 일측면에 있어서, 상기 균주는 기탁번호가 KCTC 14461BP인, 균주를 제공한다.In one aspect of the present invention, the strain provides an accession number of KCTC 14461BP, the strain.
본 발명의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 포함하는 미생물 제제를 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a microbial preparation comprising one or more of.
본 발명의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 치주 질환의 예방, 개선 또는 치료가 필요한 대상에게 치주 질환을 예방, 개선 또는 치료하는 방법을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a method for preventing, improving or treating periodontal disease to a subject in need of prevention, improvement or treatment of periodontal disease, including the step of using one or more of them.
본 발명의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 치아우식증의 예방, 개선 또는 치료가 필요한 대상에게 치아우식증을 예방, 개선 또는 치료하는 방법을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a method for preventing, improving or treating dental caries to a subject in need of prevention, improvement or treatment of dental caries, including the step of using one or more of them.
본 발명의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 이용하는 단계;를 포함하는 구취 예방 또는 제거가 필요한 대상에게 구취를 예방 또는 제거하는 방법을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a method for preventing or removing bad breath to a subject in need of preventing or removing bad breath, including the step of using one or more of them.
본 발명의 또 하나의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 포함하는 치주 질환의 예방, 개선 또는 치료용 조성물을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a composition for the prevention, improvement or treatment of periodontal disease comprising one or more of.
일 구현예에서, 상기 조성물은 아연을 더 포함하는, 치주 질환의 예방, 개선 또는 치료용 조성물을 제공한다.In one embodiment, the composition provides a composition for preventing, improving or treating periodontal disease, further comprising zinc.
일 구현예에서, 상기 조성물은 건강기능식품 조성물인, 치주 질환의 예방, 개선 또는 치료용 조성물을 제공한다.In one embodiment, the composition provides a composition for preventing, improving or treating periodontal disease, which is a health functional food composition.
일 구현예에 있어서, 상기 조성물은 약학 조성물, 건강기능식품 또는 의약품 조성물일 수 있다.In one embodiment, the composition may be a pharmaceutical composition, a health functional food or a pharmaceutical composition.
본 발명의 또 하나의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 포함하는 치아우식증의 예방, 개선 또는 치료용 조성물을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a composition for preventing, improving or treating dental caries comprising at least one of them.
일 구현예에서, 상기 조성물은 아연을 더 포함하는, 치아우식증의 예방, 개선 또는 치료용 조성물을 제공한다.In one embodiment, the composition provides a composition for preventing, improving or treating dental caries, further comprising zinc.
일 구현예에서, 상기 조성물은 건강기능식품 조성물인, 치아우식증의 예방, 개선 또는 치료용 조성물을 제공한다.In one embodiment, the composition provides a composition for preventing, improving or treating dental caries, which is a health functional food composition.
일 구현예에 있어서, 상기 조성물은 약학 조성물, 건강기능식품 또는 의약품 조성물일 수 있다.In one embodiment, the composition may be a pharmaceutical composition, a health functional food or a pharmaceutical composition.
본 발명의 또 하나의 다른 측면은 상기 본 발명의 일측면 중 어느 하나에 따른 균주; 이의 파쇄물; 이의 배양물; 이의 발효물; 및 상기 균주, 파쇄물, 배양액 또는 발효물의 추출물; 중 하나 이상을 포함하는 구취 제거 또는 예방용 조성물을 제공한다.Another aspect of the present invention is the strain according to any one of the aspects of the present invention; its shreds; its culture; its ferment; and extracts of the strains, lysates, cultures or fermented products; It provides a composition for removing or preventing bad breath comprising at least one of.
일 구현예에서, 상기 조성물은 아연을 더 포함하는, 구취 제거 또는 예방용 조성물을 제공한다.In one embodiment, the composition provides a composition for removing or preventing bad breath, further comprising zinc.
일 구현예에서, 상기 조성물은 건강기능식품 조성물인, 구취 제거 또는 예방용 조성물을 제공한다.In one embodiment, the composition provides a health functional food composition, a composition for removing or preventing bad breath.
일 구현예에 있어서, 상기 조성물은 약학 조성물, 건강기능식품 또는 의약품 조성물일 수 있다.In one embodiment, the composition may be a pharmaceutical composition, a health functional food or a pharmaceutical composition.
예시적인 일 구현예에 따르면, 상기 조성물은 약학 조성물인 것일 수 있다.According to an exemplary embodiment, the composition may be a pharmaceutical composition.
상기 약학 조성물은 유효성분 이외에 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/ 또는 완충제 등의 약제학적 보조제 및 기타 개선적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 경구 투여제 또는 비경구 투여제 형태로 제형화할 수 있다. 상기 경구 투여제는 예를 들면, 정제, 환제, 경질 및 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 분제, 산제, 세립제, 과립제, 펠렛제 등이 있으며, 이들 제형은 유효성분 이외에 계면 활성제, 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로오스 및 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및 폴리에틸렌 글리콜)를 함유할 수 있다. 정제는 또한 마그네슘 알루미늄 실리케이트, 전분페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카복시메틸셀룰로오스 및 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제, 흡수제, 착색제, 향미제, 및 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.In addition to the active ingredient, the pharmaceutical composition may further contain pharmaceutical adjuvants such as preservatives, stabilizers, wetting agents or emulsification accelerators, salts and/or buffers for regulating osmotic pressure, and other useful substances for improvement, in a conventional method. It can be formulated in the form of various oral administration or parenteral administration according to the needs. The oral administration agents include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, etc., and these formulations contain surfactants in addition to active ingredients. , diluents (e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (e.g. silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycol) . Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt It may contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavoring agents, and sweetening agents. The tablet may be prepared by a conventional mixing, granulating or coating method.
예시적인 일 구현예에 따르면, 상기 조성물은 식품 조성물인 것일 수 있다. 상기 식품 조성물은 액상 또는 고체 상태의 제형일 수 있고, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용될 수 있다. 각 제형의 식품 조성물은 유효성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다. 본 명세서에 개시된 유효성분 외에 함유할 수 있는 액체 성분에는 특별한 제한점이 없으며, 통상의 음료와 같이 여러가지 향미제 또는 천연 탄수화물 등을 추가성분으로 포함할 수 있다. 상기 천연 탄수화물의 예로는 모노사카라이드, 포도당, 과당 등의 디사카라이드, 말토스, 슈크로스 등의 폴리사카라이드, 덱스트린, 시클로덱스트린 등의 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올 등이 있다. 상기의 향미제로는 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성향미제(예를 들어 사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 명세서에 개시된 조성물 100 ml 당 일반적으로 약 1 내지 20 g, 일 측면에서 약 5 내지 12 g일 수 있다. 상기 식품 조성물은 일 측면에서 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그 염, 알긴산 및 그 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있다.According to an exemplary embodiment, the composition may be a food composition. The food composition may be in a liquid or solid form, for example, various foods, beverages, gum, tea, vitamin complexes, health supplements, etc., to be used in powder, granule, tablet, capsule or beverage form. can In the food composition of each formulation, ingredients commonly used in the field other than the active ingredient can be appropriately selected and formulated by those skilled in the art without difficulty depending on the formulation or purpose of use, and when applied simultaneously with other raw materials, a synergistic effect may occur. There is no particular limitation on the liquid ingredients that can be contained in addition to the active ingredients disclosed herein, and it may include various flavoring agents or natural carbohydrates as additional ingredients like conventional beverages. Examples of the natural carbohydrate include monosaccharides, disaccharides such as glucose and fructose, polysaccharides such as maltose and sucrose, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol etc. As the flavoring agent, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate is generally about 1 to 20 g per 100 ml of the composition disclosed herein, and in one aspect, about 5 to 12 g. In one aspect, the food composition contains various nutrients, vitamins, minerals ( electrolyte), synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, It may contain preservatives, glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like.
일 구현예에 있어서, 상기 조성물은 치약 또는 가글액의 형태로 제공될 수 있다.In one embodiment, the composition may be provided in the form of toothpaste or mouthwash.
일 구현예에 있어서, 상기 조성물은 인간을 대상으로 사용될 수 있다.In one embodiment, the composition can be used for humans.
일 구현예에 있어서, 상기 조성물은 인간 이외의 동물, 바람직하게 반려동물, 더 바람직하게 개 및 고양이의 구취제거를 위해 사용될 수 있다.In one embodiment, the composition can be used for deodorization of non-human animals, preferably companion animals, more preferably dogs and cats.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들 실시예에 의해 한정되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.
실시예 1. 락토바실러스 퍼멘텀 BCC-LF-01 균주의 분리Example 1. Isolation of Lactobacillus Fermentum BCC-LF-01 strain
한국인에게 맞는 신규 균주를 선발하기 위해 건강한 한국인 아기 및 성인의 분변, 모유 등을 시료로 사용하였다. 시료 1g을 멸균 식염수에 10배 연속 희석한 후 희석액 0.1mL를 MRS 고체배지에 도말하여 혐기조건에서 3일간 배양하였다. 생성된 단일 콜로니를 MRS 액체배지에 37℃, 18시간 동안 순수 배양하였다.To select new strains suitable for Koreans, feces and breast milk from healthy Korean babies and adults were used as samples. 1 g of the sample was serially diluted 10-fold in sterile saline, and 0.1 mL of the diluted solution was smeared on MRS solid medium and cultured for 3 days under anaerobic conditions. The resulting single colonies were purely cultured in MRS broth at 37° C. for 18 hours.
실시예 2. 락토바실러스 퍼멘텀 BCC-LF-01 균주의 당 이용성Example 2. Sugar availability of Lactobacillus permentum BCC-LF-01 strain
선별된 균주의 당 이용성을 분석하기 위해 API 50 CH kit(BioMerieux, Lyon, France)를 사용하여 49개의 탄소원에 대한 이용성을 확인하였다. MRS 고체배지에서 배양된 균주의 콜로니를 2 MacFarland의 탁도로 조절하여 현탁액을 제조하였다. 탁도를 맞춘 API 50 CHL medium을 API 50CH 스트립 튜브에 120 ㎕씩 분주하고 큐플에 미네랄 오일(mineral oil)을 2 방울씩 첨가하여 37℃에서 24 시간 및 48 시간 동안 배양하여 당 이용 패턴을 확인하였다. 동정 결과는 API web 프로그램(https://apiweb.biomerieux.com) 을 사용하여 확인하였다. 동정결과, 도 1에 표시된 바와 같이 락토바실러스 퍼멘텀과 96.4% 로 동일함을 나타내었다.In order to analyze the sugar availability of the selected strains, the availability of 49 carbon sources was confirmed using the
실시예 3. 퍼멘텀 균주의 동정Example 3. Identification of Fermentum Strain
1) 16S rRNA 서열 분석1) 16S rRNA sequence analysis
균주의 동정을 위해 Solgent (Daejeon, Korea)에 16S rRNA 서열분석을 의뢰하였다. 균주의 순수배양액 1mL에서 Wizard genomic DNA purification kit (Promega, USA)를 이용하여 DNA를 추출하였으며, 추출된 DNA를 주형으로 16S rRNA 영역을 27F(AGAGTTTGATCMTGGCTCAG), 1492R (TACGGYTACCTTGTTACGACTT) primer로 PCR을 수행하여 DNA sequencing (Solgent)을 진행하였다. 염기서열 분석 결과를 토대로 NCBI의 BLAST 상의 Genebank 데이터베이스에 등록된 다른 표준균주와 상동성을 비교하였다. 16S rRNA sequencing was commissioned to Solgent (Daejeon, Korea) for identification of the strain. DNA was extracted from 1 mL of the pure culture medium of the strain using the Wizard genomic DNA purification kit (Promega, USA), and the extracted DNA was used as a template and the 16S rRNA region was subjected to PCR with 27F (AGAGTTTGATCMTGGCTCAG) and 1492R (TACGGYTACCTTGTTACGACTT) primers. Sequencing (Solgent) was performed. Based on the sequencing results, homology with other standard strains registered in the Genebank database on BLAST of NCBI was compared.
염기서열 분석 결과 서열번호 1의 염기서열을 가지며, 신규 균주는 Lactobacillus fermentum CIP 102980과 99.93% 의 상동성을 나타내었다. Mega 7 program을 이용하여 상동성을 분석하고 계통도를 얻었다 (도 2).As a result of the nucleotide sequence analysis, it has the nucleotide sequence of SEQ ID NO: 1, and the novel strain showed 99.93% homology with Lactobacillus fermentum CIP 102980. Homology was analyzed using Mega 7 program and a phylogenetic tree was obtained (FIG. 2).
2) PCR profiles2) PCR profiles
균주에서 분리한 DNA를 주형으로 특정 부분의 specific 한 Lactobacillus fermentum primer Forward (AGGGGCTCCCTAAGCTACAG), Reverse (TGATCGCCATAAGCATACGA) 를 이용하여 PCR을 수행하였다. 본 발명에 해당되는 균주와 비교분석을 위해 한국생명공학연구원에서 분양받은 Lactobacillus fermentum KCTC 5049를 대조군으로 사용하였고 서열 간 차이를 도 3에 나타내었다.Using the DNA isolated from the strain as a template, PCR was performed using Lactobacillus fermentum primer Forward (AGGGGCTCCCTAAGCTACAG) and Reverse (TGATCGCCATAAGCATACGA) specific to a specific part. For comparative analysis with the strain corresponding to the present invention, Lactobacillus fermentum KCTC 5049 purchased from the Korea Research Institute of Bioscience and Biotechnology was used as a control, and the difference between the sequences is shown in FIG. 3 .
분석결과, Lactobacillus fermentum BCC-LF-01은 Lactobacillus fermentum KCTC 5049의 서열과 차이를 보였으며 기존의 Lactobacillus fermentum과는 다른 신규한 균주임을 확인하였다.As a result of the analysis, Lactobacillus fermentum BCC-LF-01 was different from the sequence of Lactobacillus fermentum KCTC 5049, and it was confirmed that it was a novel strain different from the existing Lactobacillus fermentum .
이에 본 발명자는 상기 균주를 신규한 락토바실러스 퍼멘텀 균주로 동정하였고, Lactobacillus fermentum BCC-LF-01로 명명하여 한국생명공학연구원 생물자원센터에 2021년 1월 27일자로 기탁하였다 (기탁번호 KCTC 14461BP).Accordingly, the present inventor identified the strain as a novel Lactobacillus fermentum strain, named Lactobacillus fermentum BCC-LF-01, and deposited it at the Korea Research Institute of Biotechnology and Biotechnology Biological Resources Center on January 27, 2021 (Accession No. KCTC 14461BP) ).
실험예 1. 항염 효과 확인Experimental Example 1. Confirmation of anti-inflammatory effect
구강 내 염증의 예방 또는 개선을 위한 목적으로 균주의 항염 효과를 세포 내 IL-12 및 IL-10 조절 능력을 평가하여 선발하였다.For the purpose of preventing or improving oral inflammation, the anti-inflammatory effect of the strain was selected by evaluating the ability to regulate intracellular IL-12 and IL-10.
분리된 균의 항염 효과를 측정하기 위해 enzyme-linked immunosorbent assay(ELISA) kit를 이용하여 실험을 수행하였다. Raw 264.7세포는 10% 우태아형청(FBS), penicillin(100 IU/mL), streptomycin(100 mg/mL)이 첨가된 DMEM 배지에 배양하였다. 24 well plate에 5 x 105 cells/mL 농도로 Raw264.7 세포를 분주하였으며, 분주하고 4시간 후 non-serum 및 항생제가 첨가되지 않은 DMEM 배지 0.5 mL로 교체해 주었다.To measure the anti-inflammatory effect of the isolated bacteria, an experiment was performed using an enzyme-linked immunosorbent assay (ELISA) kit. Raw 264.7 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 IU/mL), and streptomycin (100 mg/mL). Raw264.7 cells were dispensed at a concentration of 5 x 10 5 cells/mL in a 24-well plate, and after 4 hours of dispensing, 0.5 mL of non-serum and antibiotic-free DMEM medium was replaced.
각 균주를 1 x 108 CFU/mL 의 농도가 되도록 Raw 264.7 세포 위에 다시 접종하고 lipopolysaccharide(LPS) (1 mg/mL) 1ul 처리한 뒤, 5% CO2 존재 하에 37 ℃에서 24시간 동안 배양하였다. 배양 후 각 well에서 조심스럽게 배지를 수거, 원심분리 한 후 상등액을 취한 다음 상등액에 포함된 IL-12 및 IL-10양을 ELISA Kit (Cusabio, USA)를 사용하여 측정하였다.Each strain was inoculated again on Raw 264.7 cells to a concentration of 1 x 10 8 CFU/mL, treated with 1ul of lipopolysaccharide (LPS) (1 mg/mL), and incubated at 37 °C in the presence of 5% CO 2 for 24 hours. . After culture, the medium was carefully collected from each well, centrifuged, and the supernatant was taken, and the amount of IL-12 and IL-10 contained in the supernatant was measured using an ELISA Kit (Cusabio, USA).
음성 대조군으로는 균주 미처리군, 양성 대조군으로는 LPS (Lipopolysaccharide, Sigma)를 각각 1 mg /mL의 농도로 처리한 샘플을 사용하였다. 분리균주와 비교분석을 위해 한국생명공학연구원에서 분양받은 Lactobacillus rhamnosus GG KCTC 5033 (LGG로 표기)을 대조군으로 사용하였다. 모든 실험은 3회 반복하였고 평균값을 표준편차(SD)와 함께 도 4에 나타냈다. 또한, 도 4a 내지 도 4c 에 그래프로 제시했다.As a negative control group, a strain untreated group, and as a positive control group, samples treated with LPS (Lipopolysaccharide, Sigma) at a concentration of 1 mg/mL were used. For comparative analysis with the isolated strain, Lactobacillus rhamnosus GG KCTC 5033 (indicated as LGG) purchased from the Korea Research Institute of Bioscience and Biotechnology was used as a control group. All experiments were repeated three times and the average value is shown in FIG. 4 together with the standard deviation (SD). It is also presented graphically in FIGS. 4A to 4C .
항염능을 보이는 32개의 균주 중에서 IL-12를 유의하게 감소시키며, 동시에 IL-10을 유의하게 증가시키는 11개 균주를 선별하였다. 결과는 도 4a에 방사형 그래프로 나타내었다.Among the 32 strains showing anti-inflammatory activity, 11 strains that significantly decreased IL-12 and significantly increased IL-10 were selected. The results are shown as a radial graph in FIG. 4A .
염증 반응 시 초기 Th1면역계의 cytokine stimulator인 IL-12 사이토카인은 상기 도 4b에서 확인되듯이, 선발된 11개의 균주 처리 시 LPS를 처리하여 대식세포에서 IL-12 분비를 유도한 군과 비교하였을 때, 최소 75% 내지 100% 정도의 매우 유의한 수준으로 IL-12 분비를 억제시키는 결과가 확인되었다. The IL-12 cytokine, a cytokine stimulator of the initial Th1 immune system during the inflammatory response, was compared with the group that induced IL-12 secretion in macrophages by treatment with LPS when the 11 selected strains were treated, as shown in FIG. 4b. , the result of suppressing IL-12 secretion to a very significant level of at least 75% to 100% was confirmed.
이 중 10균주 (BCC-LF-01, BCC-LF-02, BCC-LCL-02, BCC-STT-02, BCC-LR-08, BCC-LR-12, BCC-LG-12, BCC-LG-18, BCC-LG-19, BCC-LPG-14)는 항염 분야에서 효과가 공지된 LGG (LPS 처리군 대비 80% 감소)보다 더 우수한 수준이었다.Of these, 10 strains (BCC-LF-01, BCC-LF-02, BCC-LCL-02, BCC-STT-02, BCC-LR-08, BCC-LR-12, BCC-LG-12, BCC-LG -18, BCC-LG-19, BCC-LPG-14) were superior to LGG (80% reduction compared to the LPS treatment group) with a known anti-inflammatory effect.
또한, IL-10(Interleukin-10)은 대표적인 항염증성 사이토카인으로 Th2 세포에서 분비된다. In addition, IL-10 (Interleukin-10) is a representative anti-inflammatory cytokine and is secreted from Th2 cells.
상기 도 4c에서 확인할 수 있는 바와 같이, 11균주 (BCC-LF-01, BCC-LF-02, BCC-LCL-02, BCC-STT-02, BCC-LR-08, BCC-LR-12, BCC-LG-01, BCC-LG-12, BCC-LG-18, BCC-LG-19, BCC-LPG-14)는 LPS를 처리하여 대식세포에서 IL-10 분비를 유도한 군보다도 20% 내지 높게는 300% 수준으로 IL-10의 분비를 증가시켰다. 이는 대조군으로 사용된 LGG와 비교하였을 때, 매우 유의한 (p<0.001) 수준이었다.As can be seen in Figure 4c, 11 strains (BCC-LF-01, BCC-LF-02, BCC-LCL-02, BCC-STT-02, BCC-LR-08, BCC-LR-12, BCC -LG-01, BCC-LG-12, BCC-LG-18, BCC-LG-19, BCC-LPG-14) were 20% to higher than the group in which IL-10 secretion was induced in macrophages by treatment with LPS. increased IL-10 secretion to a level of 300%. This was a very significant ( p <0.001) level when compared to LGG used as a control.
이러한 사실을 종합하여 볼 때, 본 발명에서 항염능으로 선발된 11균주는 대식세포내에서 염증반응에 영향을 미치는 IL-12및 IL-10을 유의미하게 조절할 수 있는 결과를 보였고, 이는 항염능에 있어 LGG보다 훨씬 우수한 유산균 재료임을 분명하게 입증한다.Taken together, the 11 strains selected for anti-inflammatory activity in the present invention showed a result that could significantly regulate IL-12 and IL-10, which affect the inflammatory response in macrophages, It clearly proves that it is a much superior lactic acid bacteria material than LGG.
실험예 2. 구강 유해 미생물에 대한 항균 효과 확인Experimental Example 2. Confirmation of antibacterial effect on oral harmful microorganisms
본 발명의 락토바실러스 퍼멘텀 BCC-LF-01(Lactobacillus fermentum BCC-LF-01)의 균체에 있어, 구강 세균에 대한 항균 활성을 Spot assay 방법을 이용하여 평가하였다. In the cells of Lactobacillus fermentum BCC-LF-01 of the present invention, the antibacterial activity against oral bacteria was evaluated using the Spot assay method.
1)유산균 배양1) Lactobacillus culture
기존에 구강 세균 억제 효능이 알려진 균주 Weissella cibaria (WC)와 치주질환에 대한 항염 효과가 알려진 Lactobacillus brevis (LB)는 각각 제품으로부터 분리하여 대조군으로 사용하였다. 항염 상위 11균주와 대조군 2균주는 MRS 액체배지에 접종 후 37℃, 18시간 배양하였다. Weissella cibaria (WC), a strain known for its efficacy in inhibiting oral bacteria, and Lactobacillus brevis (LB), known for its anti-inflammatory effect on periodontal disease, were each separated from the product and used as a control. The top 11 anti-inflammatory strains and the 2 control strains were inoculated in MRS broth and incubated at 37° C. for 18 hours.
2) 병원성균 배양2) Culture of pathogenic bacteria
본 실험에서 사용된 균주는 치아우식증과 관련된 균주 스트렙토코커스 뮤탄스(Streptococcus mutans KCTC 3065)는 한국생명공학연구원에서 분양받아 Brain heart infusion 배지에서 37℃ 48시간 호기 배양하여 사용하였다. The strain used in this experiment was a dental caries-related strain Streptococcus mutans (KCTC 3065), which was purchased from the Korea Research Institute of Bioscience and Biotechnology and was aerobically cultured at 37°C for 48 hours in Brain heart infusion medium.
본 실험에서 사용된 포르피로모나스 진지발리스(Porphyromonas gingivalis KCTC 5352)는 한국생명공학연구원에서, 푸조박테리움 뉴클레아툼 (Fusobacterium nucleatum KCOM 1205)은 한국구강미생물자원은행에서 분양 받아 modified Brain heart infusion (5㎍/mL hemin, 1㎍/mL menadione, 0.05% cysteine) 배지에서 37℃ 48시간 혐기 배양하여 사용하였다. Porphyromonas gingivalis KCTC 5352 used in this experiment was purchased from the Korea Research Institute of Bioscience and Biotechnology, and Fusobacterium nucleatum KCOM 1205 was purchased from the Korea Oral Microorganism Resources Bank and modified Brain heart infusion ( 5 μg/mL hemin, 1 μg/mL menadione, 0.05% cysteine) was used after anaerobic culture at 37° C. for 48 hours.
3) 항균 활성3) antibacterial activity
유산균 배양한 후 원심분리하여 상등액을 제거한 뒤, 1X PBS로 1번 균체를 세척한 다음 0.85% saline 용액에 1 x 109 CFU/mL 수준으로 희석하고, 병원성균은 0.85% saline 용액에 1 x 107 CFU/mL 수준으로 희석하였다. After culturing lactic acid bacteria, centrifugation to remove the supernatant, wash the
20mL씩 분주하여 건조된 MRS 고체배지에 균수가 조정된 병원성 균을 100㎕ 분주하여 스프레더로 도말한 다음 병원성균이 도말된 배지 위에 유산균체 희석액 10㎕를 떨어트려 말린 뒤, 37℃, 48시간 혐기 배양하여 유산균체 주변에 생성된 억제환을 측정하였다.After dispensing 20 mL of the dried MRS solid medium with 100 μl of the adjusted pathogenic bacteria, spread it with a spreader, and then drop 10 μl of the lactic acid bacteria dilution on the medium smeared with the pathogenic bacteria and dry it, 37° C., anaerobic for 48 hours. By culturing, the inhibition ring generated around the lactic acid bacteria was measured.
병원성균에 대한 억제환은 Scan 500 Automatic colony counter(Interscience, France)를 이용하여 촬영 및 측정하여 평가하였다. 항균활성 결과는 도 5에 나타냈다. Inhibition of pathogenic bacteria was evaluated by photographing and measuring using a
Pre-test로서 항염 상위 11균주를 스트렙토코커스 뮤탄스에 대해 항균효과가 있는지 확인하였다. 그 결과, BCC-LR-12, BCC-LR-08, BCC-LF-01, BCC-LF-02 총 4균주가 항균 활성이 있는 것으로 확인되었다. 선별된 4균주로 포르피로모나스 진지발리스와 푸조박테리움 뉴클레아툼에 대한 항균활성 실험을 진행하였다.As a pre-test, it was confirmed whether the top 11 anti-inflammatory strains had an antibacterial effect against Streptococcus mutans. As a result, a total of 4 strains BCC-LR-12, BCC-LR-08, BCC-LF-01, and BCC-LF-02 were confirmed to have antibacterial activity. Antibacterial activity tests were performed on Porphyromonas gingivalis and Puzobacterium nucleatum with the selected 4 strains.
도 5a에서 나타난 바와 같이, BCC-LF-01 균주가 스트렙토코커스 뮤탄스(Streptococcus mutans)에 대해 29mm의 가장 큰 억제환을 형성하였다.As shown in Fig. 5a, the BCC-LF-01 strain formed the largest inhibitory ring of 29mm against Streptococcus mutans .
도 5b에 나타난 바와 같이, BCC-LF-01는 포르피로모나스 진지발리스(Porphyromonas gingivalis)에 대해 16.7mm의 억제환을 형성하였으며 이는Weissella cibaria 보다 더 높은 항균활성을 나타내었다. 반면에 Lactobacillus brevis 는 항균활성을 나타내지 않았다.As shown in FIG. 5b , BCC-LF-01 formed an inhibitory ring of 16.7 mm against Porphyromonas gingivalis , which exhibited higher antibacterial activity than Weissella cibaria . On the other hand, Lactobacillus brevis did not show antibacterial activity.
도 5c에 나타난 바와 같이, 분리 균주들은 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum)에 대해 Weissella cibaria 보다 더 높은 항균활성을 나타내었다(23mm이상). 특히 BCC-LF-01은 26.1mm의 가장 큰 억제환을 형성하였다. 반면에 Lactobacillus brevis 는 항균활성을 나타내지 않았다.As shown in Fig. 5c, the isolated strains exhibited higher antibacterial activity than Weissella cibaria against Fusobacterium nucleatum (23mm or more). In particular, BCC-LF-01 formed the largest inhibitory ring of 26.1 mm. On the other hand, Lactobacillus brevis did not show antibacterial activity.
도 5에 나타난 바와 같이, 항균활성 결과, 신규 Lactobacillus fermentum BCC-LF-01는 분리된 균주 중에서 스트렙토코커스 뮤탄스 (Streptococcus mutans), 포르피로모나스 진지발리스 (Porphyromonas gingivalis), 푸조박테리움 뉴클레아툼 (Fusobacterium nucleatum)에 대해 항균 활성이 가장 우수하였다.As shown in Figure 5, as a result of the antibacterial activity, the novel Lactobacillus fermentum BCC-LF-01 is Streptococcus mutans among the isolated strains, Porphyromonas gingivalis ( Porphyromonas gingivalis ), Puzobacterium nucleatum ( Fusobacterium nucleatum ) The antibacterial activity was the best.
특히, 스트렙토코커스 뮤탄스(Streptococcus mutans)에 대해 60% 이상 항균 활성이 보고된 Weissella cibaria 보다 Lactobacillus fermentum BCC-LF-01의 항균력이 더 높았으며 포르피로모나스 진지발리스 (Porphyromonas gingivalis), 푸조박테리움 뉴클레아툼 (Fusobacterium nucleatum)에 대해서도 Weissella cibaria보다 높은 항균 활성이 확인되었다.In particular, the antibacterial activity of Lactobacillus fermentum BCC-LF-01 was higher than that of Weissella cibaria , which was reported to have an antibacterial activity of more than 60% against Streptococcus mutans , and Porphyromonas gingivalis ), Puzobacterium Higher antibacterial activity than Weissella cibaria was also confirmed for nucleatum ( Fusobacterium nucleatum ).
분리 균주 중에서Lactobacillus fermentum BCC-LF-01 균주가 구강질환 원인균의 성장을 우수하게 억제하였다. Among the isolated strains, the Lactobacillus fermentum BCC-LF-01 strain excellently inhibited the growth of bacteria causing oral diseases.
실험예 3. 아르기닌 데이미나아제 활성 확인Experimental Example 3. Confirmation of arginine deiminase activity
아르기닌 데이미나아제(arginine deiminase, ADI) 활성이 있는 균주를 선별하기 위해 아르기닌을 기질로, phenol red를 지시약으로 사용하여 배지 (yeast extract 2g/L, peptone 2g/L, L-arginine 10g/L, ammonium chloride 1.5g/L, K2HPO4 1g/L, NaCl 0.02 g/L, MgSO4·7H2O 0.5g/L, MnSO4 0.1g/L, FeSO4 0.005g/L, glucose 10g/L, agar 20g/L, phenol red dye 0.12g/L, pH6.6)를 제조하였다. To select strains with arginine deiminase (ADI) activity, medium (yeast extract 2g/L, peptone 2g/L, L-arginine 10g/L, ammonium chloride 1.5 g/L, K 2 HPO 4 1 g/L, NaCl 0.02 g/L, MgSO 4 7H 2 O 0.5 g/L, MnSO 4 0.1 g/L, FeSO 4 0.005 g/L, glucose 10 g/L , agar 20g/L, phenol red dye 0.12g/L, pH6.6) was prepared.
IL-12와 IL-10 실험을 통해 1차적으로 선별된 11개 항염 균주를 아르기닌이 첨가된 배지에 접종하여 37℃에서 24시간 혐기 배양하였다. ADI는 아르기닌을 시트룰린과 암모니아로 분해시키는 효소로, ADI를 생성하는 균주의 콜로니는 암모니아에 의해 배지의 pH가 증가하여 분홍색으로 변한다. 따라서 아르기닌이 첨가된 배지에서 분홍색 콜로니를 나타내는 균주를 선별하였다. The 11 anti-inflammatory strains primarily selected through IL-12 and IL-10 experiments were inoculated into an arginine-added medium and cultured anaerobically at 37° C. for 24 hours. ADI is an enzyme that decomposes arginine into citrulline and ammonia, and colonies of strains that produce ADI turn pink by increasing the pH of the medium by ammonia. Therefore, strains showing pink colonies in the arginine-added medium were selected.
항염 11개의 선별 균주 중 아르기닌 데이미나아제 활성을 지닌 균주는 BCC-LF-01, BCC-LF-02, BCC-LCL-02 총 3균주로 확인되었다 (표1).Among the 11 anti-inflammatory strains selected, three strains with arginine deiminase activity were identified as BCC-LF-01, BCC-LF-02, and BCC-LCL-02 (Table 1).
IL-12 및 IL-10 분비능, 구강 유해균주에 대한 항균활성, 아르기닌 데이미나아제 활성 실험 결과를 토대로 다기능 구강 유산균으로써 Lactobacillus fermentum BCC-LF-01 균주를 최종적으로 선별하였다. The Lactobacillus fermentum BCC-LF-01 strain was finally selected as a multifunctional oral lactic acid bacteria based on the IL-12 and IL-10 secretion ability, antibacterial activity against oral harmful strains, and arginine deiminase activity test results.
상기와 같은 실시예 및 실험예로부터 본원발명 발명자들은 신규한Lactobacillus fermentum BCC-LF-01 균주가 항염 효과를 지니면서 치주질환, 치아우식증 및 구취 원인균을 효과적으로 억제함으로써 치주질환, 치아우식증 및 구취 예방 또는 개선에 유용함을 확인하였다. From the above Examples and Experimental Examples, the inventors of the present invention found that the novel Lactobacillus fermentum BCC-LF-01 strain effectively inhibits periodontal disease, dental caries and bad breath causative bacteria while having an anti-inflammatory effect, thereby preventing periodontal disease, dental caries and bad breath or It was confirmed that it is useful for improvement.
<110> Bioeleven co., Ltd. <120> Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof <130> DP-2020-0769 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1459 <212> DNA <213> Unknown <220> <223> 16s rRNA of BCC-LF-01 <400> 1 tgcctaatac atgcaagtcg aacgcgttgg cccaattgat tgatggtgct tgcacctgat 60 tgattttggt cgccaacgag tggcggacgg gtgagtaaca cgtaggtaac ctgcccagaa 120 gcgggggaca acatttggaa acagatgcta ataccgcata acagcgttgt tcgcatgaac 180 aacgcttaaa agatggcttc tcgctatcac ttctggatgg acctgcggtg cattagcttg 240 ttggtggggt aacggcctac caaggcgatg atgcatagcc gagttgagag actgatcggc 300 cacaatggga ctgagacacg gcccatactc ctacgggagg cagcagtagg gaatcttcca 360 caatgggcgc aagcctgatg gagcaacacc gcgtgagtga agaagggttt cggctcgtaa 420 agctctgttg ttaaagaaga acacgtatga gagtaactgt tcatacgttg acggtattta 480 accagaaagt cacggctaac tacgtgccag cagccgcggt aatacgtagg tggcaagcgt 540 tatccggatt tattgggcgt aaagagagtg caggcggttt tctaagtctg atgtgaaagc 600 cttcggctta accggagaag tgcatcggaa actggataac ttgagtgcag aagagggtag 660 tggaactcca tgtgtagcgg tggaatgcgt agatatatgg aagaacacca gtggcgaagg 720 cggctacctg gtctgcaact gacgctgaga ctcgaaagca tgggtagcga acaggattag 780 ataccctggt agtccatgcc gtaaacgatg agtgctaggt gttggagggt ttccgccctt 840 cagtgccgga gctaacgcat taagcactcc gcctggggag tacgaccgca aggttgaaac 900 tcaaaggaat tgacgggggc ccgcacaagc ggtggagcat gtggtttaat tcgaagctac 960 gcgaagaacc ttaccaggtc ttgacatctt gcgccaaccc tagagatagg gcgtttcctt 1020 cgggaacgca atgacaggtg gtgcatggtc gtcgtcagct cgtgtcgtga gatgttgggt 1080 taagtcccgc aacgagcgca acccttgtta ctagttgcca gcattaagtt gggcactcta 1140 gtgagactgc cggtgacaaa ccggaggaag gtggggacga cgtcagatca tcatgcccct 1200 tatgacctgg gctacacacg tgctacaatg gacggtacaa cgagtcgcga actcgcgagg 1260 gcaagcaaat ctcttaaaac cgttctcagt tcggactgca ggctgcaact cgcctgcacg 1320 aagtcggaat cgctagtaat cgcggatcag catgccgcgg tgaatacgtt cccgggcctt 1380 gtacacaccg cccgtcacac catgagagtt tgtaacaccc aaagtcggtg gggtaacctt 1440 ttaggagcca gccgcctaa 1459 <110> Bioeleven co., Ltd. <120> Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof <130> DP-2020-0769 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1459 <212> DNA <213> Unknown <220> <223> 16s rRNA of BCC-LF-01 <400> 1 tgcctaatac atgcaagtcg aacgcgttgg cccaattgat tgatggtgct tgcacctgat 60 tgattttggt cgccaacgag tggcggacgg gtgagtaaca cgtaggtaac ctgcccagaa 120 gcgggggaca acattggaa acagatgcta ataccgcata acagcgttgt tcgcatgaac 180 aacgcttaaa agatggcttc tcgctatcac ttctggatgg acctgcggtg cattagcttg 240 ttggtggggt aacggcctac caaggcgatg atgcatagcc gagttgagag actgatcggc 300 cacaatggga ctgagacacg gcccatactc ctacgggagg cagcagtagg gaatcttcca 360 caatgggcgc aagcctgatg gagcaacacc gcgtgagtga agaagggttt cggctcgtaa 420 agctctgttg ttaaagaaga acacgtatga gagtaactgt tcatacgttg acggtattta 480 accagaaagt cacggctaac tacgtgccag cagccgcggt aatacgtagg tggcaagcgt 540 tatccggatt tattgggcgt aaagagagtg caggcggttt tctaagtctg atgtgaaagc 600 cttcggctta accggagaag tgcatcggaa actggataac ttgagtgcag aagagggtag 660 tggaactcca tgtgtagcgg tggaatgcgt agatatatgg aagaacacca gtggcgaagg 720 cggctacctg gtctgcaact gacgctgaga ctcgaaagca tgggtagcga acaggattag 780 ataccctggt agtccatgcc gtaaacgatg agtgctaggt gttggagggt ttccgccctt 840 cagtgccgga gctaacgcat taagcactcc gcctggggag tacgaccgca aggttgaaac 900 tcaaaggaat tgacgggggc ccgcacaagc ggtggagcat gtggtttaat tcgaagctac 960 gcgaagaacc ttaccaggtc ttgacatctt gcgccaaccc tagagatagg gcgtttcctt 1020 cgggaacgca atgacaggtg gtgcatggtc gtcgtcagct cgtgtcgtga gatgttgggt 1080 taagtcccgc aacgagcgca acccttgtta ctagttgcca gcattaagtt gggcactcta 1140 gtgagactgc cggtgacaaa ccggaggaag gtggggacga cgtcagatca tcatgcccct 1200 tatgacctgg gctacacacg tgctacaatg gacggtacaa cgagtcgcga actcgcgagg 1260 gcaagcaaat ctcttaaaac cgttctcagt tcggactgca ggctgcaact cgcctgcacg 1320 aagtcggaat cgctagtaat cgcggatcag catgccgcgg tgaatacgtt cccgggcctt 1380 gtacacaccg cccgtcacac catgagagtt tgtaacaccc aaagtcggtg gggtaacctt 1440 ttaggagcca gccgcctaa 1459
Claims (25)
아르기닌 데이미나아제 (Arginine deiminase) 활성을 갖는 항염효과가 있는,
기탁번호가 KCTC 14461BP인 락토바실러스 퍼멘텀 (Lactobacillus fermentum ) BCC-LF-01 균주.
Streptococcus mutans ( Streptococcus mutans ), Porphyromonas gingivalis ( Porphyromonas gingivalis ) and Fusobacterium nucleatum ( Fusobacterium nucleatum ) Has antibacterial activity against harmful microorganisms in the oral cavity,
Arginine deiminase (Arginine deiminase) has an anti-inflammatory effect with activity,
Accession number KCTC 14461BP Lactobacillus fermentum ( Lactobacillus fermentum ) BCC-LF-01 strain.
상기 균주는 IL-12의 생성을 감소시키며, IL-10의 생성을 증가시키는 항염 효과가 있는, 균주.
According to claim 1,
The strain reduces the production of IL-12, and has an anti-inflammatory effect to increase the production of IL-10, the strain.
상기 균주는 치주질환 예방, 개선 또는 치료 효과가 있는, 균주.
According to claim 1,
The strain has a periodontal disease prevention, improvement or treatment effect, the strain.
상기 균주는 치아우식증 예방, 개선 또는 치료 효과가 있는, 균주.
According to claim 1,
The strain has a dental caries prevention, improvement or treatment effect, the strain.
상기 균주는 구취 제거 또는 예방 효과가 있는, 균주.
According to claim 1,
The strain is effective in removing or preventing bad breath, the strain.
상기 균주는 서열번호 1의 염기서열을 포함하는 16S rRNA를 갖는, 균주.
According to claim 1,
The strain has a 16S rRNA comprising the nucleotide sequence of SEQ ID NO: 1, the strain.
A strain according to any one of claims 1, 2, 4, 6, 8 and 10; its shreds; its culture; its ferment; and an extract of the strain, lysate, culture or ferment; A composition for preventing or improving periodontal disease comprising at least one of.
상기 조성물은 아연을 더 포함하는, 치주 질환의 예방 또는 개선용 조성물.
12. The method of claim 11,
The composition further comprises zinc, a composition for preventing or improving periodontal disease.
상기 조성물은 건강기능식품인, 치주 질환의 예방 또는 개선용 조성물.
12. The method of claim 11,
The composition is a health functional food, a composition for preventing or improving periodontal disease.
A strain according to any one of claims 1, 2, 4, 6, 8 and 10; its shreds; its culture; its ferment; and an extract of the strain, lysate, culture or ferment; A composition for preventing or improving dental caries comprising one or more of.
상기 조성물은 아연을 더 포함하는, 치아우식증의 예방 또는 개선용 조성물.
16. The method of claim 15,
The composition further comprises zinc, a composition for preventing or improving dental caries.
상기 조성물은 건강기능식품인, 치아우식증의 예방 또는 개선용 조성물.
16. The method of claim 15,
The composition is a health functional food, a composition for preventing or improving dental caries.
A strain according to any one of claims 1, 2, 4, 6, 8 and 10; its shreds; its culture; its ferment; and an extract of the strain, lysate, culture or ferment; A composition for removing or preventing bad breath comprising at least one of.
상기 조성물은 아연을 더 포함하는, 구취 제거 또는 예방용 조성물.
20. The method of claim 19,
The composition further comprises zinc, a composition for removing or preventing bad breath.
상기 조성물은 건강기능식품인, 구취 제거 또는 예방용 조성물.
20. The method of claim 19,
The composition is a health functional food, a composition for removing or preventing bad breath.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210039918A KR102360233B1 (en) | 2021-03-26 | 2021-03-26 | Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof |
| PCT/KR2022/003883 WO2022203302A1 (en) | 2021-03-26 | 2022-03-21 | Strain of lactobacillus fermentum having effect of preventing or ameliorating oral disease and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210039918A KR102360233B1 (en) | 2021-03-26 | 2021-03-26 | Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102360233B1 true KR102360233B1 (en) | 2022-02-09 |
Family
ID=80265942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210039918A KR102360233B1 (en) | 2021-03-26 | 2021-03-26 | Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102360233B1 (en) |
| WO (1) | WO2022203302A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022203302A1 (en) * | 2021-03-26 | 2022-09-29 | 주식회사 헥토헬스케어 | Strain of lactobacillus fermentum having effect of preventing or ameliorating oral disease and use thereof |
| KR102478041B1 (en) | 2022-05-11 | 2022-12-16 | 주식회사 엠제이바이오젠 | Novel Lactobacillus acidophilus strain MJCD175 as potential probiotics for oral health and use thereof |
| KR20240029230A (en) | 2022-08-26 | 2024-03-05 | (주) 바이텍 | Composition for improving oral health comprising lactic acid bacterial and dead cell of lactic acid bacteria |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080091743A (en) * | 2008-09-22 | 2008-10-14 | 광주과학기술원 | Pharmaceutical and food compositions for preventing or treating arthritis comprising lactic acid bacteria and collagen as active ingredients |
| KR20110019420A (en) * | 2008-06-11 | 2011-02-25 | 바스프 에스이 | Use and methods for preventing and/or treating oral malodour |
| KR20140053981A (en) * | 2011-08-05 | 2014-05-08 | 가부시키가이샤 야쿠르트 혼샤 | Prophylactic or therapeutic agent for oral diseases |
| KR101681810B1 (en) | 2014-06-05 | 2016-12-01 | 동국대학교 경주캠퍼스 산학협력단 | Ginseng preparations containing abundant ginsenoside using a beauveria bassiana and method thereof |
| KR20190082739A (en) * | 2017-01-31 | 2019-07-10 | 경희대학교 산학협력단 | Novel lactic acid bacteria and use thereof |
| KR102198552B1 (en) * | 2020-06-09 | 2021-01-05 | 주식회사 비피도 | Composition improving, preventing or treating halitosis or dental caries comprising Lactobacillus fermentum OK derived from human oral cavity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102360233B1 (en) * | 2021-03-26 | 2022-02-09 | (주)바이오일레븐 | Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof |
-
2021
- 2021-03-26 KR KR1020210039918A patent/KR102360233B1/en active IP Right Grant
-
2022
- 2022-03-21 WO PCT/KR2022/003883 patent/WO2022203302A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110019420A (en) * | 2008-06-11 | 2011-02-25 | 바스프 에스이 | Use and methods for preventing and/or treating oral malodour |
| KR20080091743A (en) * | 2008-09-22 | 2008-10-14 | 광주과학기술원 | Pharmaceutical and food compositions for preventing or treating arthritis comprising lactic acid bacteria and collagen as active ingredients |
| KR20140053981A (en) * | 2011-08-05 | 2014-05-08 | 가부시키가이샤 야쿠르트 혼샤 | Prophylactic or therapeutic agent for oral diseases |
| KR101681810B1 (en) | 2014-06-05 | 2016-12-01 | 동국대학교 경주캠퍼스 산학협력단 | Ginseng preparations containing abundant ginsenoside using a beauveria bassiana and method thereof |
| KR20190082739A (en) * | 2017-01-31 | 2019-07-10 | 경희대학교 산학협력단 | Novel lactic acid bacteria and use thereof |
| KR102198552B1 (en) * | 2020-06-09 | 2021-01-05 | 주식회사 비피도 | Composition improving, preventing or treating halitosis or dental caries comprising Lactobacillus fermentum OK derived from human oral cavity |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022203302A1 (en) * | 2021-03-26 | 2022-09-29 | 주식회사 헥토헬스케어 | Strain of lactobacillus fermentum having effect of preventing or ameliorating oral disease and use thereof |
| KR102478041B1 (en) | 2022-05-11 | 2022-12-16 | 주식회사 엠제이바이오젠 | Novel Lactobacillus acidophilus strain MJCD175 as potential probiotics for oral health and use thereof |
| KR20240029230A (en) | 2022-08-26 | 2024-03-05 | (주) 바이텍 | Composition for improving oral health comprising lactic acid bacterial and dead cell of lactic acid bacteria |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022203302A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102360233B1 (en) | Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof | |
| KR102360232B1 (en) | Lactobacillus plantarum having effects of preventing or improving oral disease and the use thereof | |
| CN104277998B (en) | Use and method for preventing and/or treating oral malodor | |
| EP1483366B1 (en) | Antimicrobial composition | |
| NO329324B1 (en) | Combination of lactic acid bacteria and their use for the preparation of a nutritional supplement, hygiene product or pharmaceutical preparation for the prevention and / or treatment of infections and inflammatory disorders. | |
| KR101164876B1 (en) | Broccoli production fermented by lactic acid bacteria, which is anti-inflammatory and anti-Helicobacter pylori and method for preparation thereof | |
| KR102173168B1 (en) | A composition for improving intestine function comprising genus Leuconostoc | |
| KR102495163B1 (en) | Streptococcus salivarius strain having anti-inflammatory and antibacterial activity and uses thereof | |
| KR102095339B1 (en) | Novel lactobacillus reuteri and composition for preventing or treating periodontal diseases comprising the same | |
| KR101062779B1 (en) | Bifidobacterium adolescentis inhibiting the growth of streptococcus mutans and foodstuffs and pharmaceutical composition for preventing tooth decay containing bifidobacterium adolescentis or its culture | |
| JP2006508943A (en) | Methods for inhibiting yeast growth | |
| KR102478041B1 (en) | Novel Lactobacillus acidophilus strain MJCD175 as potential probiotics for oral health and use thereof | |
| KR20200032672A (en) | NOVEL STRAIN OF Lactobacillus plantarum AND COMPOSITION FOR PREVENTING OR TREATING OF INFLAMMATORY DISEASE USING THE SAME | |
| EP4374845A1 (en) | Composition comprising superoxide dismutase and/or bacillus strain spores, and use thereof for improving oral health | |
| KR102491640B1 (en) | Weissella cibaria strain for suppressing dental caries inducing bacteria and use thereof | |
| JP2017143802A (en) | Method of culturing lactobacillus lactic acid bacteria | |
| TWI733207B (en) | Lactobacillus plantarum strain, composition comprising the same, method of producing the same and its use for inhibiting or reducing oral pathogens | |
| KR101723103B1 (en) | A composition comprising fermented artemisia annua extract and fermented red ginseng concentrated powder for preventing, improving or treating inflammation induced virulence of oral bacteria | |
| KR102632524B1 (en) | Composition for prevention or treatment periodontal diseases comprising Bacillus velezensis, culture media or culture supernatant thereof as active ingredient | |
| KR102620909B1 (en) | Novel Lactiplantibacillus plantarum SKO-001 and use thereof | |
| KR20240014328A (en) | Weissella cibaria having effects of preventing or improving oral disease and the use thereof | |
| EP4070804A1 (en) | Agent for preventing or ameliorating periodontal disease | |
| KR20220032506A (en) | Novel Bacillus velezensis and use thereof | |
| KR20220032507A (en) | Bacillus subtilis and use thereof | |
| EP3837993A1 (en) | Composition for improving intestinal function comprising leuconostoc sp. strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |